BMS sees positive outcome for cancer drug

Bristol-Myers Squibb says its cancer drug ixabepilone has demonstrated activity in a Phase II trial for metastatic breast cancer among patients resistant to three types of chemotherapy. The trial involved 126 patients in a single-arm study.

"Drug resistance is a major concern in treating patients with advanced disease," said Renzo Canetta, vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. "The results of this study are important as they provide valuable information about this investigational compound and its potential in patients with advanced breast cancer that is no longer responding to any of the current U.S. approved chemotherapy treatments."

- here's the release

ALSO: BMS has scrubbed a partnership with Medivir to develop MIV-170 for HIV. Medivir said the drug did not meet BMS' desired profile. Release

Related Articles:
Better times ahead for BMS? Report
BMS unveils positive diabetes data. Report
Patent victory reignites rumors of BMS takeover. Report
Probation draws to a close for Bristol-Myers. Report

Suggested Articles

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.